sinemet 25 mg/250 mg tablett
merck sharp & dohme bv - karbidopa (monohydrat); levodopa - tablett - 25 mg/250 mg - levodopa 250 mg aktiv substans; karbidopa (monohydrat) 27 mg aktiv substans - levodopa och dekarboxylashämmare
sinemet 25 mg/250 mg tablett
orifarm ab - karbidopa (monohydrat); levodopa - tablett - 25 mg/250 mg - karbidopa (monohydrat) 27 mg aktiv substans; levodopa 250 mg aktiv substans - levodopa och dekarboxylashämmare
sinemet depot 50 mg/200 mg depottablett
orifarm ab - karbidopa (monohydrat); levodopa - depottablett - 50 mg/200 mg - levodopa 200 mg aktiv substans; karbidopa (monohydrat) 54 mg aktiv substans - levodopa och dekarboxylashämmare
sinemet depot 50 mg/200 mg depottablett
orifarm ab - karbidopa (monohydrat); levodopa - depottablett - 50 mg/200 mg - levodopa 200 mg aktiv substans; karbidopa (monohydrat) 54 mg aktiv substans - levodopa och dekarboxylashämmare
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacciner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. användning av detta vaccin bör ske i enlighet med officiella rekommendationer.
bendamustine accord 2,5 mg/ml pulver till koncentrat till infusionsvätska, lösning
accord healthcare b.v. - bendamustinhydroklorid - pulver till koncentrat till infusionsvätska, lösning - 2,5 mg/ml - bendamustinhydroklorid 2,5 mg aktiv substans; mannitol hjälpämne
nucala
glaxosmithkline trading services - mepolizumab - astma - läkemedel mot obstruktiv lungsjukdom, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.
xolair
novartis europharm limited - omalizumab - asthma; urticaria - läkemedel mot obstruktiv lungsjukdom, - allergiska asthmaxolair är indicerat hos vuxna, ungdomar och barn (6 till.
spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacciner - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.
bicaflac sine kalium hemofiltrationsvätska
b. braun medizintechnologie gmbh - glukosmonohydrat; kalciumkloriddihydrat; magnesiumkloridhexahydrat; natriumklorid - hemofiltrationsvätska - glukosmonohydrat 9,9 mg aktiv substans; natriumklorid 4,21 mg aktiv substans; kalciumkloriddihydrat 1,98 mg aktiv substans; magnesiumkloridhexahydrat 0,91 mg aktiv substans - hemofiltrationsvätskor